Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Ataxin-2 CRISPR/Cas9 KO Plasmid (m): sc-422807
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Ataxin-2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Ataxin-2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Ataxin-2 Antibody (A-6): sc-515602
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ataxin-2 CRISPR/Cas9 KO Plasmid (m) | sc-422807 | 20 µg | $397.00 |
Overview
Atxn2 encodes the RNA-binding protein Ataxin-2, a conserved regulator of post-transcriptional gene expression that associates with polyribosomes and ribonucleoprotein granules to influence mRNA stability and translation. In mouse cells, Ataxin-2 participates in stress granule and P-body dynamics, linking nutrient signaling and cellular stress responses to RNA metabolism. It interfaces with pathways controlling proteostasis and neuronal homeostasis, and altered ATXN2 dosage has been connected to neurodegeneration-associated processes. These features make Atxn2 a useful target for dissecting RNA regulatory networks, stress-adaptation programs, and neuronally relevant phenotypes in experimental models.
Ataxin-2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Atxn2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Atxn2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Atxn2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Ataxin-2 protein expression.
This CRISPR knockout system enables efficient generation of Atxn2-deficient cell models for investigation of Ataxin-2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Atxn2 exon(s) critical for Ataxin-2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Atxn2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Ataxin-2 CRISPR/Cas9 KO Plasmid (m) and Ataxin-2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Atxn2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Ataxin-2 HDR Plasmid (m) and Ataxin-2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Atxn2 homology arms to support homology-directed repair at defined Atxn2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.